APA (7th ed.) Citation

A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, & M. A. Proskurin. (2018). Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation. Izdatelstvo OKI.

Chicago Style (17th ed.) Citation

A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, and M. A. Proskurin. Pharmacoeconomic Analysis of Vemurafenib and Dabrafenib Use in Patients with Inoperable or Metastatic Melanoma with BRAF V600 Mutation. Izdatelstvo OKI, 2018.

MLA (9th ed.) Citation

A. S. Kolbin, et al. Pharmacoeconomic Analysis of Vemurafenib and Dabrafenib Use in Patients with Inoperable or Metastatic Melanoma with BRAF V600 Mutation. Izdatelstvo OKI, 2018.